Serum resistance and biofilm formation in clinical isolates of Acinetobacter baumannii

FEMS Immunology and Medical Microbiology

Volumn 55, Issue 3, 2009, Pages 414-421

  King, Lauren B ^a   Swiatlo, Edwin ^a   Swiatlo, Andrea ^a,b   McDaniel, Larry S ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Acinetobacter baumannii; Biofilm; Complement; Serum resistance

Indexed keywords

AZTREONAM; CIPROFLOXACIN; COMPLEMENT FACTOR H; COTRIMAZINE; GENTAMICIN; IMIPENEM; PIPERACILLIN; SULTAMICILLIN; TAZOBACTAM; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BIOFILM; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; MICROTITER PLATE ASSAY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING;

ACINETOBACTER BAUMANNII; BIOFILMS; BLOOD BACTERICIDAL ACTIVITY; COMPLEMENT C3; COMPLEMENT C3 CONVERTASE, ALTERNATIVE PATHWAY; COMPLEMENT FACTOR H; COMPLEMENT SYSTEM PROTEINS; HUMANS; PROTEIN BINDING;

EID: 62149149136     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2009.00538.x     Document Type: Article

References (47)

1. Anstey NM, Currie BJ, Hassell M, Palmer D, Dwyer B Seifert H (2002) Community-acquired bacteremic Acinetobacter pneumonia in tropical Australia is caused by diverse strains of Acinetobacter baumannii, with carriage in the throat in at-risk groups. J Clin Microbiol 40 : 685 686.
2. Bergogne-Berezin E Towner KJ (1996) Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 9 : 148 165.
3. Bernabeu-Wittel M, Pichardo C, Garcia-Curiel A, Pachon-Ibanez ME, Ibanez-Martinez J, Jimenez-Mejias ME Pachon J (2005) Pharmacokinetic/ pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia. Clin Microbiol Infec 11 : 319 325.
4. Blom AM (2002) Structural and functional studies of complement inhibitor C4b-binding protein. Biochem Soc T 30 : 978 982.
5. Blom AM, Villoutreix BO Dahlback B (2004) Complement inhibitor C4b-binding protein-friend or foe in the innate immune system? Mol Immunol 40 : 1333 1346.
6. Chen MZ, Hsueh PR, Lee LN, Yu CJ, Yang PC Luh KT (2001) Severe community-acquired pneumonia due to Acinetobacter baumannii. Chest 120 : 1072 1077.
7. Dave S, Brooks-Walter A, Pangburn MK McDaniel LS (2001) PspC, a pneumococcal surface protein, binds human factor H. Infect Immun 69 : 3435 3437.
8. Dave S, Carmicle S, Hammerschmidt S, Pangburn MK McDaniel LS (2004a) Dual roles of PspC, a surface protein of Streptococcus pneumoniae, in binding human secretory IgA and factor H. J Immunol 173 : 471 477.
9. Dave S, Pangburn MK, Pruitt C McDaniel LS (2004b) Interaction of human factor H with PspC of Streptococcus pneumoniae. Indian J Med Res 119 (suppl) : 66 73.
10. Davis KA, Moran KA, McAllister CK Gray PJ (2005) Multidrug-resistant Acinetobacter extremity infections in soldiers. Emerg Infect Dis 11 : 1218 1224.
11. DiScipio RG (1992) Ultrastructures and interactions of complement factors H and I. J Immunol 149 : 2592 2599.
12. Ecker JA, Massire C, Hall TA et al 2006) Identification of Acinetobacter species and genotyping of Acinetobacter baumannii by multilocus PCR and mass spectrometry. J Clin Microbiol 44 : 2921 2932.
13. Falagas ME Karveli EA (2007) The changing global epidemiology of Acinetobacter baumannii infections: a development with major public health implications. Clin Microbiol Infec 13 : 117 119.
14. Fournier PE Richet H (2006) The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 42 : 692 699.
15. Fournier PE, Vallenet D, Barbe V et al 2006) Comparative genomics of multidrug resistance in Acinetobacter baumannii. PLoS Genet 2 : e7.
16. Garcia A, Solar H, Gonzalez C Zemelman R (2000) Effect of EDTA on the resistance of clinical isolates of Acinetobacter baumannii to the bactericidal activity of normal human serum. J Med Microbiol 49 : 1047 1050.
17. Gaynes R Edwards JR (2005) Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 41 : 848 854.
18. Harry L Mobley JWW (1996) Urinary Tract Infections: Molecular Pathogenesis and Clinical Management. ASM Press, Washington, DC.
19. Jain R Danziger LH (2004) Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann Pharmacother 38 : 1449 1459.
20. Joly-Guillou ML (2005) Clinical impact and pathogenicity of Acinetobacter. Clin Microbiol Infec 11 : 868 873.
21. Kraiczy P Wurzner R (2006) Complement escape of human pathogenic bacteria by acquisition of complement regulators. Mol Immunol 43 : 31 44.
22. Krushkal J, Bat O Gigli I (2000) Evolutionary relationships among proteins encoded by the regulator of complement activation gene cluster. Mol Biol Evol 17 : 1718 1730.
23. Landman D, Quale JM, Mayorga D et al 2002) Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned. Arch Intern Med 162 : 1515 1520.
24. Li J, Nation RL, Owen RJ, Wong S, Spelman D Franklin C (2007) Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains. Clin Infect Dis 45 : 594 598.
25. Maegele M, Gregor S, Steinhausen E et al 2005) The long-distance tertiary air transfer and care of tsunami victims: injury pattern and microbiological and psychological aspects. Crit Care Med 33 : 1136 1140.
26. Morgan BP, Daha M, Meri S Nicholson-Weller A (2000) Into the third century of complement research. Immunol Today 21 : 603 605.
27. Munoz-Price LS Weinstein RA (2008) Acinetobacter infection. New Engl J Med 358 : 1271 1281.
28. Oncul O, Keskin O, Acar HV et al 2002) Hospital-acquired infections following the 1999 Marmara earthquake. J Hosp Infect 51 : 47 51.
29. Pantopoulou A, Giamarellos-Bourboulis EJ, Raftogannis M et al 2007) Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: the significance of co-administration of rifampicin. Int J Antimicrob Ag 29 : 51 55.
30. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN Bonomo RA (2007) Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Ch 51 : 3471 3484.
31. Pitts B, Hamilton MA, Zelver N Stewart PS (2003) A microtiter-plate screening method for biofilm disinfection and removal. J Microbiol Meth 54 : 269 276.
32. Quin LR, Carmicle S, Dave S, Pangburn MK, Evenhuis JP McDaniel LS (2005) In vivo binding of complement regulator factor H by Streptococcus pneumoniae. J Infect Dis 192 : 1996 2003.
33. Quin LR, Onwubiko C, Carmicle S McDaniel LS (2006) Interaction of clinical isolates of Streptococcus pneumoniae with human complement factor H. FEMS Microbiol Lett 264 : 98 103.
34. Quin LR, Onwubiko C, Moore QC, Mills MF, McDaniel LS Carmicle S (2007) Factor H binding to PspC of Streptococcus pneumoniae increases adherence to human cell lines in vitro and enhances invasion of mouse lungs in vivo. Infect Immun 75 : 4082 4087.
35. Ram S, Mackinnon FG, Gulati S et al 1999) The contrasting mechanisms of serum resistance of Neisseria gonorrhoeae and group B Neisseria meningitidis. Mol Immunol 36 : 915 928.
36. Rice LB (2006) Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 43 (suppl 2) : S100 S105.
37. Richet H Fournier PE (2006) Nosocomial infections caused by Acinetobacter baumannii: a major threat worldwide. Infect Cont Hosp Ep 27 : 645 646.
38. Rodriguez-Bano J, Marti S, Soto S et al 2008) Biofilm formation in Acinetobacter baumannii: associated features and clinical implications. Clin Microbiol Infec 14 : 276 278.
39. Rooijakkers SH van Strijp JA (2007) Bacterial complement evasion. Mol Immunol 44 : 23 32.
40. Schlaf G, Beisel N, Pollok-Kopp B, Schieferdecker H, Demberg T Gotze O (2002) Constitutive expression and regulation of rat complement factor H in primary cultures of hepatocytes, Kupffer cells, and two hepatoma cell lines. Lab Invest 82 : 183 192.
41. Siegel RE (2008) Emerging gram-negative antibiotic resistance: daunting challenges, declining sensitivities, and dire consequences. Respir Care 53 : 471 479.
42. Swords WE, Moore ML, Godzicki L, Bukofzer G, Mitten MJ VonCannon J (2004) Sialylation of lipooligosaccharides promotes biofilm formation by nontypeable Haemophilus influenzae. Infect Immun 72 : 106 113.
43. Talbot GH, Bradley J, Edwards Jr. JE, Gilbert D, Scheld M Bartlett JG (2006) Bad bugs need drugs: an update on the development pipeline from the antimicrobial availability task force of the infectious diseases society of America. Clin Infect Dis 42 : 657 668.
44. van Dessel H, Kamp-Hopmans TE, Fluit AC et al 2002) Outbreak of a susceptible strain of Acinetobacter species 13 (sensu Tjernberg and Ursing) in an adult neurosurgical intensive care unit. J Hosp Infect 51 : 89 95.
45. Van Looveren M Goossens H (2004) Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infec 10 : 684 704.
46. Villegas MV Hartstein AI (2003) Acinetobacter outbreaks, 1977-2000. Infect Cont Hosp Ep 24 : 284 295.
47. Vogel U, Weinberger A, Frank R, Muller A, Kohl J, Atkinson JP Frosch M (1997) Complement factor C3 deposition and serum resistance in isogenic capsule and lipooligosaccharide sialic acid mutants of serogroup B Neisseria meningitidis. Infect Immun 65 : 4022 4029.